Allergan – which is set to be acquired by AbbVie in a $63 billion deal announced ... that it had implemented a recall of textured breast implants “in certain international markets.” ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

whereas Coal Plant emphasized its advancements in the regenerative breast implant program and ongoing strategic partnerships, including one with pharmaceutical giant AbbVie. These developments ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...

Healthcare & Pharmaceuticalscategory· February 7, 2025 US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections AbbVie said on Friday that the U.S. Food and Drug Administration ...

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 29 trades. If we consider the specifics of each trade ...

AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...